Atea Pharmaceuticals, Inc.
AVIRNASDAQHealthcare● Active
$4.32
+$0.07(+1.65%)
Market Cap$345717068
P/E Ratio—
52W High$6.45
52W Low$2.78
Atea Pharmaceuticals, Inc. (AVIR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AVIR · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.35B |
| Cost of Revenue | $0.00B | $0.08B | $0.07B | $0.06B | $0.17B |
| Gross Profit | $0.00B | ($0.08B) | ($0.07B) | ($0.06B) | $0.18B |
| Gross Margin %(computed) | — | — | — | — | 52.41% |
| Operating Expenses | |||||
| R&D Expenses | $0.15B | $0.15B | $0.13B | $0.09B | $0.17B |
| G&A Expenses | $0.03B | $0.05B | $0.05B | $0.05B | $0.05B |
| Total Operating Expenses | $0.18B | $0.11B | $0.09B | $0.07B | $0.05B |
| Operating Income | ($0.18B) | ($0.19B) | ($0.16B) | ($0.13B) | $0.14B |
| Operating Margin %(computed) | — | — | — | — | 39.38% |
| Interest Income | $0.02B | $0.03B | $0.03B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.01B | $0.00B |
| Income Before Tax | ($0.16B) | ($0.17B) | ($0.13B) | ($0.12B) | $0.14B |
| Income Tax Expense | ($0.01B) | $0.00B | $0.00B | ($0.00B) | $0.02B |
| Net Income | ($0.16B) | ($0.17B) | ($0.14B) | ($0.12B) | $0.12B |
| Net Margin %(computed) | — | — | — | — | 34.49% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.94 | $-2.00 | $-1.63 | $-1.39 | $1.46 |
| Wtd Avg Shares | 0.08B | 0.08B | 0.08B | 0.08B | 0.08B |
| EBITDA | ($0.18B) | ($0.13B) | ($0.12B) | ($0.11B) | $0.14B |
| EBITDA Margin %(computed) | — | — | — | — | 39.39% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Atea Pharmaceuticals, Inc. data
About Atea Pharmaceuticals, Inc. (AVIR) Income Statement
Atea Pharmaceuticals, Inc. (AVIR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AVIR reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.16B) — a net profit margin of —.
Frequently asked questions
AVIR · 4 questionsAtea Pharmaceuticals, Inc. (AVIR) reported revenue of $0.00B for 2025, down —% year-over-year.
AVIR revenueAVIR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09